Publication of List of Manufacturers Suspended from Licensing for the Manufacture of Therapeutic Goods - Royal Adelaide Hospital Radiopharmacy

Overview

The Therapeutic Goods Act 1989 was enacted to regulate the supply of therapeutic goods in Australia, ensuring their quality, safety, and efficacy. The Act was introduced to address the need for comprehensive regulation of therapeutic goods, including medicines, medical devices, and blood and blood components. This was necessary to protect public health by ensuring that only safe and effective therapeutic goods are available for use. Enacted by the Commonwealth Parliament, the Act aims to provide a robust framework for the regulation of therapeutic goods, ensuring they meet the required standards before being made available to the public. The policy objective of the Act is to safeguard public health by controlling the quality, safety, and efficacy of therapeutic goods supplied in Australia. This legislative approach helps maintain high standards in the therapeutic goods industry, thereby protecting consumers from substandard or unsafe products.

Scope and Application

The Therapeutic Goods Act 1989 governs the regulation of therapeutic goods in Australia, encompassing a broad range of products such as medicines, medical devices, and blood and tissues. This Act applies to various entities including manufacturers, importers, sponsors, and suppliers of therapeutic goods, ensuring their safety, quality, and efficacy. The Act imposes obligations on these entities to obtain appropriate licences and permits, and mandates adherence to specific standards and regulations. The scope of the Act extends nationally, affecting all therapeutic goods distributed or manufactured within Australia, regardless of the manufacturer's location or the end user's jurisdiction. However, certain products may be exempt from certain licensing requirements under specific conditions, such as those intended for personal use or small-scale research. The Act also empowers the Therapeutic Goods Administration to issue notices and suspend licences as necessary, as evidenced in the published notice concerning the suspension of Royal Adelaide Hospital Radiopharmacy’s manufacturing licence. This regulatory mechanism ensures compliance and maintains the integrity of the therapeutic goods market. The application and enforcement of the Act can be further detailed and modified through subordinate instruments, thereby allowing for flexibility and precision in its implementation.

Key Provisions

The Therapeutic Goods Act 1989, as amended and supplemented by the Gazette, contains a provision under Section 41(1)(d) that allows for the suspension of a licence to manufacture therapeutic goods. In the case of the Royal Adelaide Hospital Radiopharmacy, their licence number MI-12112004-LI-000163-1, has been suspended at their request. This suspension is effective from 30 May 2016 to 31 December 2016, as published in the Gazette by Hongxia Jin, the Delegate of the Secretary of the Department of Health. The obligations of the manufacturer under the Therapeutic Goods Act 1989 are significant. They must adhere to the standards and regulations set forth by the Therapeutic Goods Administration, ensuring that all therapeutic goods produced meet the necessary safety, quality, and efficacy standards. The manufacturer is also required to maintain thorough records and documentation related to their manufacturing processes, and to promptly report any adverse events or issues to the TGA. Additionally, the manufacturer must comply with any directives or requests from the TGA, including the provision of information or samples for inspection and evaluation. Failure to comply with the Therapeutic Goods Act 1989 can result in serious consequences. Offences under the Act can lead to criminal charges, with penalties including fines of up to $2,100,000 for corporations and $210,000 for individuals, as stipulated under Section 32 of the Act. Civil penalties can also be imposed, with fines of up to $22,000 per day for ongoing breaches. In addition to financial penalties, non-compliance can lead to the suspension or revocation of the manufacturer's licence, effectively halting their operations. These stringent measures are in place to ensure that therapeutic goods available in Australia meet the highest standards of safety and quality.